CHMP positive opinion recommending approval of Benlysta for adult patients with active lupus nephritis
The Pharma Data
MARCH 26, 2021
The adverse reactions observed in BLISS-LN were consistent with the known safety profile of Benlysta administered intravenously plus standard therapy in patients with SLE. Belimumab was approved as an IV formulation in July 2011, and as a subcutaneous (SC) formulation in adults in November 2017. About the BLISS-LN study.
Let's personalize your content